TC BioPharm (TCBP) shares rose as much as almost 25% in recent trading Tuesday after the company said that negotiations with its acquisition targets are progressing.
The company is looking to expand its therapeutic platform through acquisitions focusing on new indications and cell therapy approaches.
"Management is currently negotiating deal terms in good faith, and I believe the process is progressing to mutually beneficial outcomes," TC BioPharm Chief Executive Bryan Kobel said.
The company did not identify the acquisition candidates.
Price: 0.64, Change: +0.03, Percent Change: +5.10